VERONA PHARMA PLC - ADR
VERONA PHARMA PLC - ADR logo
VRNA

VERONA PHARMA PLC - ADR (VRNA)

$21.193.37%

Market is closed
– opens on 8 PM, 06 Feb 2023
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$20.06
Day's Range
$21.6
$3.41
52-Week Range
$26.44
1 month return16.01%
3 month return67.91%
1 year return251.99%
5 year return275.04%

Analyst Recommendation

based on 13 analysts ratings

Buy
92%
Buy
7%
Hold
0%
Sell

Based on 13 Wall street analysts offering stock ratings for VERONA PHARMA PLC - ADR(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 39.55%

Current

$21.19

Target

$29.57

Recommendation Trend

Based on 13 analyst

Current1M Ago3M Ago
Buy
12
5
12
Hold
1
0
1
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization1.6B
Book Value$3.16
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-0.99
PEG Ratio0.0
Wall Street Target Price29.57

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)4.14
Enterprise Value756.5M
Enterprise Value/Revenue20.96
Enterprise Value/Ebitda-9.4

Technicals

Beta0.14
50 Day MA19.01
200 Day MA10.52

Institutional Holdings

RA Capital Management, LLC

8.0%

Orbimed Advisors, LLC

7.53%

NEA Management Company, LLC

7.39%

Perceptive Advisors LLC

6.67%

Vivo Capital, LLC

5.62%

Wellington Management Company LLP

5.52%

Company Information

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE ('Ensifentrine as a Novel inHAled Nebulized COPD thErapy') for COPD maintenance treatment. The Company raised gross proceeds of $200 million through a private placement in July 2020 and expects the funds to support its operations and Phase 3 clinical program into 2023. Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler ('DPI') and pressurized metered-dose inhaler ('pMDI'). Ensifentrine is being evaluated in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases.
OrganizationVERONA PHARMA PLC - ADR
Employees24
CEODr. David S. Zaccardelli
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is VERONA PHARMA PLC - ADR share price today?

Can Indians buy VERONA PHARMA PLC - ADR shares?

How can I buy VERONA PHARMA PLC - ADR shares from India?

Can Fractional shares of VERONA PHARMA PLC - ADR be purchased?

What are the documents required to start investing in VERONA PHARMA PLC - ADR stocks?

What are today’s High and Low prices of VERONA PHARMA PLC - ADR?

What are today’s traded volumes of VERONA PHARMA PLC - ADR?

What is today’s market capitalisation of VERONA PHARMA PLC - ADR?

What is the 52 Week High and Low Range of VERONA PHARMA PLC - ADR?

How much percentage VERONA PHARMA PLC - ADR is down from its 52 Week High?

How much percentage VERONA PHARMA PLC - ADR is up from its 52 Week low?

What are the historical returns of VERONA PHARMA PLC - ADR?

Who is the Chief Executive Officer (CEO) of VERONA PHARMA PLC - ADR?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*